

Xtant Medical Partners with B2i Digital to Educate Investors on Its Orthobiologics Innovation and Market Opportunity

Partnership will deliver centralized investor-focused content for investors to gain insight into Xtant's orthobiologics platform and long-term value proposition

NEW YORK, NY, UNITED STATES, July 28, 2025 /EINPresswire.com/ -- [B2i Digital](#) is pleased to announce that [Xtant Medical Holdings \(NYSE American: XTNT\)](#) has been named a B2i Digital Featured Company. [Xtant is a global medical technology company](#) that develops, manufactures, and markets a full-service portfolio of regenerative medicine products and related medical devices for orthopedic and neurosurgical specialists.



The company's vertically integrated model allows it to offer a full-service product line that includes bone-healing grafts, growth-factor biologics, cellular allografts, synthetics, and amnion products.

The company's vertically integrated model allows it to offer a full-service product line that includes bone-healing grafts, growth-factor biologics, cellular allografts, synthetics, and amnion products. This integration, combined with a robust R&D pipeline that includes multiple next-generation biologics scheduled for launch through 2025, underpins its strategy for driving margin improvement and long-term, sustainable growth.

"We are pleased to showcase Xtant Medical to our investor community at this pivotal time in the company's expansion and evolution," said David Shapiro, CEO of B2i Digital. "With its vertically integrated platform covering all five major orthobiologic categories and a clear trajectory of revenue growth, the company presents a compelling story for investors interested in the medical technology sector. Xtant's established distribution network and robust product pipeline position it well within a multi-billion-dollar market."

Sean Browne, CEO of Xtant Medical, commented, "Our partnership with B2i Digital will help us share our growth story and the value of our comprehensive biologics platform to the investment

community. We are focused on execution and believe this collaboration will enhance our connection with current and prospective shareholders."

Xtant Medical has demonstrated strong business fundamentals, reporting fiscal year 2024 revenue of \$117.5 million, a 29% year-over-year increase. The company has established significant market access through 450 integrated delivery network (IDN) contracts and a network of over 670 independent distributors, serving a \$2.5 billion U.S. orthobiologics market within a \$10.1 billion global spine market.

About B2i Digital, Inc.

B2i Digital, Inc. partners with investor conferences, public companies, and capital markets advisors through its Featured Conference, Featured Company, and Featured Expert programs. The firm

“

We are pleased to showcase Xtant Medical to our investor community at this pivotal time in their expansion and evolution. They have an established distribution network and a robust product pipeline.”

David Shapiro, CEO of B2i Digital

leverages digital marketing technologies, a network of 1.3 million investors, and targeted introductions to connect key players in the markets. B2i Digital was founded in 2021 by David Shapiro, previously the Chief Marketing Officer and an investment banker at Maxim Group, LLC. David was also one of the founders of Maxim's investor awareness platform, M-Vest.com.

B2i Digital Contact Information:
David Shapiro
Chief Executive Officer

B2i Digital, Inc.

<https://b2idigital.com>

212.579.4844 Office

david@b2idigital.com

<https://www.linkedin.com/in/davidshapironyc>

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and



Xtant Medical has demonstrated strong business fundamentals, reporting fiscal year 2024 revenue of \$117.5 million, a 29% year-over-year increase.

complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

Investor Contact Information:

Kevin Gardner

Managing Director

LifeSci Advisors

646.889.1200

KGardner@lifesciadvisors.com

<https://www.linkedin.com/company/xtant-medical/>

David Shapiro

B2i Digital, Inc.

+1 212-579-4844

david@b2idigital.com

Visit us on social media:

[LinkedIn](#)

[Bluesky](#)

[Instagram](#)

[Facebook](#)

[YouTube](#)

[TikTok](#)

[X](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/834872984>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.